Adagene (ADAG)
(Delayed Data from NSDQ)
$2.25 USD
+0.13 (6.13%)
Updated Sep 19, 2024 03:59 PM ET
After-Market: $2.24 -0.01 (-0.44%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
ADAG 2.25 +0.13(6.13%)
Will ADAG be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ADAG based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ADAG
Are Medical Stocks Lagging Adagene (ADAG) This Year?
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?
ADAG: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is MannKind (MNKD) Stock Outpacing Its Medical Peers This Year?
Are Medical Stocks Lagging Boston Scientific (BSX) This Year?
Are Medical Stocks Lagging Medpace (MEDP) This Year?
Other News for ADAG
Buy Rating Affirmed on Adagene: Promising ADG126 Clinical Data and Market Underappreciation
Adagene’s ADG126 Shows Promise in MSS CRC Therapy
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody? ADG126 (Muzastotug) in Combination with KEYTRUDA? (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
Adagene to Participate in Investor Conferences in September